AbstrAct to determine the safety and efficacy of 2 consecutive doses of triclabendazole (tcbZ) in the treatment of Schistosoma mansoni infection in human cases infected with both S. mansoni and Fasciola sp., we conducted a field survey involving 6314 individuals from 15 villages. the overall prevalence of schistosomiasis alone was 15.8%, of fascioliasis alone 2.2%, and of combined infection 0.7%. treatment with 2 doses of tcbZ was given to the 49 cases with combined infection. Eight weeks after treatment, the cure rate was 96% for fascioliasis and was 32.7% for schistosomiasis. All schistosomiasis cases cured had a low intensity infection. Liver function tests done before treatment and 8 weeks after substantiate the safety of 2 doses of tcbZ given to those with combined infection. Administration of tcbZ should precede praziquantel in treatment of combined infection, however tcbZ cannot be recommended for infection with S. mansoni alone. 
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Introduction
In Egypt, despite government efforts aimed at control, schistosomiasis remains an important public health problem. It is still endemic in rural areas and transmission is still ongoing [1] . Human fascioliasis has emerged in Egypt over the past 3 decades and prevalence rates in rural areas range between 2% and 19% [2-5] . As a result, schistosomiasis and fascioliasis co-exist in the same environment and they prevail in some villages [6, 7] . A drug effective against both parasites would be highly welcome.
Praziquantel (PZQ) is still the ideal drug for control of schistosomiasis [8] . However, the extensive reliance on just 1 drug is of utmost concern due to the risk of possible development of drugresistant parasites. In view of this concern, there is a great need for developing novel antischistosomal drugs.
Triclabendazole (TCBZ; Egaten), an effective and safe drug for Fasciola infection, was evaluated experimentally on schistosomiasis. In vitro, adult Schistosoma mansoni worms exposed to the drug were reported to show rapid destruction of the tegument; the damage was found to be irreversible and 100% of the worms were killed after 24 hours [9] . Studies performed on experimentally-infected mice revealed conflicting results; 2 have reported 84% and 87% of worms killed 4 weeks after treatment [10, 11] , however, a more recent study found low efficacy (18%-36%) for TCBZ in vivo [12] .
No studies with high power on the effect of TCBZ on Schistosoma infection in humans are available. Recently, Barduagni et al. evaluated the use of TCBZ for treatment of patients co-infected with Fasciola sp. and Schistosoma sp. using a single dose of 10 mg/kg body weight [13] . They concluded that TCBZ was insufficiently effective on schistosomiasis. Further studies with 2 consecutive doses of TCBZ could be of value.
Methods
A field survey was carried out by the Parasitology Department of the Medical Research Institute in 15 villages near Alexandria in Beheira governorate. These villages were known to be endemic for both Schistosoma sp. and Fasciola sp. A census of the inhabitants was performed and demographic data were collected and recorded. All individuals over 5 years of age (n = 6314) were asked to submit a stool sample; there were no refusals to comply. We prepared 3 Kato-Katz slides [14] of 41.7 mg each for each sample and eggs were counted by trained technicians. Each technician examined 1 set of slides.
All positive cases with combined infection (n = 42) identified in the field survey, together with 7 cases which were referred to the Parasitology Department within the study period, were enrolled in the study. Interview and clinical examination were conducted. Participants included in the study had no past history of jaundice or viral hepatitis or history of receiving schistosomicidal or fasciolicidal drugs within the preceding 6 months.
Treatment and follow-up
Prior to treatment, a blood sample was obtained and liver function tests were performed. TCBZ for human use (Egaten, Novartis Pharma AG, Basle, Switzerland) was used. Each tablet contained 250 mg TCBZ and each case received 2 doses on 2 successive days after a fatty meal. Each dose was calculated at 10 mg/kg body weight. The maximum dose was 2.5 tablets.
For follow-up after treatment, all cases were asked to provide a stool sample after 1, 2, 3, and 8 weeks; 3 Kato-Katz slides were examined for each sample, and eggs were counted for positive cases.
Cases were considered cured of either S. mansoni or Fasciola sp. infection at any examination when no eggs of the corresponding parasites were found in stools after examination of 3 Kato-Katz slides. Actual cure was considered when eggs were absent on the 8th week after treatment.
Blood samples were taken at the 8th week and liver function tests repeated.
Statistical analysis
Data were processed using SPSS, version 11. Intensity of infection was expressed as geometric mean egg count (GMEC). Cure rates were calculated as the percentage of individuals becoming parasitologically negative. For cases remaining positive after treatment, percentage changes in egg counts were calculated using the formula:
where: b = before and a = after treatment The sign rank test was used to test the significance of changes in egg count, and the Cochrane test was used to assess changes in cure rates in the weeks of follow-up.
Ethics
The ethical aspects were respected throughout the study: informed consent was obtained from all participants and from parents of infected children. They were informed about the drug and the study protocol.
Results
The field survey covered a total of 6314 individuals from villages near Alexandria. Prevalence of schistosomiasis single infection was 15.8% (n = 996), of fascioliasis single infection was 2.2% (n = 142), and of combined infection was 0.7% (n = 42). For the 49 cases with combined infection (including the 7 referred ones) age ranged between 5 and 50 years; 27 (57%) of these were males.
Treatment of cases with combined infection
Cure rates for Fasciola and Schistosoma infection in combined cases were assessed. The cure rate for Fasciola was 98.0% (only 1 positive case) in the 1st, 2nd and 3rd week and decreased to 95.9% in the 8th week (2 cases). No significant changes in Schistosoma egg counts were found in cases remaining positive after TCBZ treatment (Table 2) .
Liver function tests are presented in Table 3 , showing no significant changes 8 weeks after treatment. No side effects were reported. Thus TCBZ is considered tolerable and safe in cases with combined infection.
Discussion
The efficacy and safety of TCBZ in treatment of Schistosoma infection was not sufficiently studied in human schistosomal infections. The existence of a relatively large number of patients infected with both Schistosoma and Fasciola detected in the present field study made it feasible and ethically accepted to assess the schistosomicidal effect of TCBZ while treating Fasciola infections in these patients. As some workers recommended the use of 2 doses of TCBZ (10 mg/kg each) in treatment 
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of Fasciola infection [15] this treatment schedule was followed to increase the possibility of detecting any potential schistosomicidal effect in cases with combined infection. In our study, according to the results of the 8th week, TCBZ cured more than one-third of the patients with combined infection. It is important to note that cases cured from schistosomiasis were generally those with low egg counts (epg < 100). Some of them ceased to pass ova starting 1 week after treatment, others became negative starting from the second week. Some cases gave varying results in the different examinations, probably due to the low sensitivity of the Kato-Katz technique to detect light infection. In cases with moderate or heavy Schistosoma infection (epg > 100), TCBZ failed to cure any case, or even to reduce the intensity of infection. This latter finding is difficult to interpret, but it raises the possibility that TCBZ is not effective on immature worms, expected to be present more frequently in patients with higher intensity of infection.
In the 8th week, the reported cure rates for fascioliasis and schistosomiasis were slightly lower than those in the first few weeks. This is possibly due to the recovery of a few worms that were affected but not killed by the drug and resumed oviposition.
Considering cases that ceased passing eggs throughout the follow-up period, the actual cure rate would amount to 16.3%.
The variability in the effect of TCBZ on Schistosoma versus Fasciola, on high intensity versus low intensity infection, and in vitro versus in vivo Schistosoma infection needs more research. Pharmacokinetics in the host might play a key role in the differing susceptibilities to TCBZ between Schistosoma and Fasciola; it might also explain the difference in the in vitro and in vivo activity of the drug on schistosomes. TCBZ was reported to be highly protein bound in animal species and, while Fasciola is known to be very susceptible to drugs that mainly bind to plasma proteins, schistosomes might be less affected by the proteinbound TCBZ [16] .
To sum up, this study emphasizes the fact that TCBZ, given in 2 consecutive doses cannot be recommended for treatment of Schistosoma infection alone because its efficacy is so inferior to that of PZQ. However, in areas where combined infection with both Schistosoma and Fasciola are prevalent, our findings indicate that the use of TCBZ followed by PZQ could be of value. Thanks are due to staff members of TDR for their encouragement during the work. Special thanks are due to the late Professor Dr Laila Abou-Basha who spent a lot of effort in the initiation of this project. 
